BeyondSpring Inc BYSI announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition.
- The comparison was made between cancer patients receiving plinabulin 40 mg (n=228) or not receiving plinabulin (n=172) and with all patients receiving myelosuppressive chemotherapy.
- Plinabulin 40 mg was given 30 minutes after chemotherapy.
- Plinabulin rapidly (within 24 hours) reversed chemo-induced myelosuppression in both the PROTECTIVE-1 and 2 studies.
- Plinabulin-mediated increases in cell numbers are dose-dependent and correlated among myeloid, lymphoid, and erythroid lineages cells.
- Related Link: BeyondSpring Shares Crater After FDA Rejects Plinabulin Application.
- Price Action: BYSI shares are up 4.91% at $4.27 during the market session on the last check Wednesday.
- Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in